Pharmacologic suppression of target cell recognition by engineered T cells expressing chimeric T-cell receptors

Area of Science:

• Immunology
• Cancer Gene Therapy
• Cellular Therapy

Background:

• Adoptive T-cell therapy using chimeric T-cell receptors (chTCRs) shows promise for treating malignancies.
• A key challenge is mitigating T-cell-mediated damage to normal tissues expressing low levels of tumor antigens.
• Controlling the activity of engineered T cells is crucial for enhancing safety.

Purpose of the Study:

• To investigate a strategy for suppressing target cell recognition by engineered T cells.
• To evaluate the efficacy of tetracycline-inducible systems in controlling chTCR-expressing T cells.
• To assess the potential of this approach for limiting on-target, off-tumor toxicity in cancer gene therapy.

Main Methods:

• Jurkat T cells were engineered to express an anti-hapten chTCR under a tetracycline-suppressible promoter.
• Engineered T cells were tested for recognition of hapten-coated (antigen-positive) and uncoated (antigen-negative) target cells.
• The effect of tetracycline treatment on chTCR expression and target cell recognition was analyzed at various effector-to-target cell ratios.

Main Results:

• Engineered T cells specifically recognized hapten-coated target cells.
• Tetracycline treatment significantly reduced chTCR expression in the engineered T cells.
• Target cell recognition by the engineered T cells was completely suppressed upon tetracycline administration.

Conclusions:

• Tetracycline-mediated suppression of chTCR activity offers a controllable method for regulating engineered T cells.
• This inducible suppression strategy may be valuable for minimizing toxicity associated with adoptive T-cell therapy.
• The findings support the development of safer and more targeted cancer gene therapies.